NCT07513454 2026-04-07
A Phase 2 Study of HW211026 in Participants With Actinic Keratosis
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Phase 2 Not yet recruiting
Clinical Trials
181 trialsNCT05662202 2026-04-03
Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp
Biofrontera Inc.
Phase 3 Active not recruiting
NCT06135415 2026-03-25
TirbAKare
Almirall, S.A.
Phase 3 Completed
NCT07144345 2026-03-05
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
Sun Pharmaceutical Industries Limited
Phase 3 Active not recruiting
NCT07428941 2026-02-24
LegitHealth PH
AI Labs Group S.L
Completed
NCT07144852 2026-02-20
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
Sun Pharmaceutical Industries Limited
Phase 3 Active not recruiting
NCT06888362 2026-01-28
Trial to Investigate GZ21T in Healthy Volunteers
Genzada Pharmaceuticals USA, Inc.
Phase 1 Completed
NCT07340697 2026-01-27
Evaluate RLS-1496 Topical Cream for Actinic Keratosis
Rubedo Life Sciences, Inc.
Phase 1/2 Recruiting
NCT07335003 2026-01-12
Study of the Photoprotection and Prevention of Actinic Damage With Anthelios Fluide 100 KA+ UVMune 400 in Patients With Multiple Actinic Keratoses
Cosmetique Active International
Phase NA Recruiting
NCT07318675 2026-01-06
A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis.
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Phase 1 Recruiting
NCT07137819 2025-08-22
EXACT-1
Aresus Pharma GmbH
Phase 3 Recruiting
NCT06319794 2025-07-18
Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis
TORQUR
Phase 2 Completed
NCT00472459 2025-04-18
Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
Galderma R&D
Phase 3 Completed
NCT01820260 2025-03-13
Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis
LEO Pharma
Phase 1/2 Completed
NCT02549352 2025-03-13
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
LEO Pharma
Phase 3 Completed
NCT03115476 2025-03-11
A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
LEO Pharma
Phase 3 Terminated
NCT01541553 2025-03-10
A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp
LEO Pharma
Phase 3 Completed
NCT01600014 2025-03-10
Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp
LEO Pharma
Phase 3 Completed
NCT01998984 2025-03-10
Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
LEO Pharma
Phase 2 Completed
NCT02305888 2025-03-10
Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively
LEO Pharma
Phase 2 Completed
NCT02361216 2025-03-10
Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest
LEO Pharma
Phase 3 Completed
NCT02547233 2025-03-10
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up
LEO Pharma
Phase 3 Completed
NCT02547363 2025-03-10
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
LEO Pharma
Phase 3 Completed
NCT02549339 2025-03-10
Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up
LEO Pharma
Phase 3 Completed
NCT01449513 2025-03-07
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy
LEO Pharma
Phase 1 Completed
NCT01926496 2025-03-07
Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
LEO Pharma
Phase 4 Completed
NCT01922050 2025-03-06
A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis
LEO Pharma
Phase 1/2 Completed
NCT02100813 2025-03-06
Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis
LEO Pharma
Phase 1/2 Completed
NCT02120456 2025-03-06
Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
LEO Pharma
Phase 1/2 Completed
NCT01387711 2025-02-24
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology
LEO Pharma
Phase 1 Completed
NCT01703078 2025-02-24
Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis
LEO Pharma
Phase 1 Completed
NCT01787383 2025-02-24
A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities
LEO Pharma
Phase 3 Completed
NCT01803477 2025-02-24
Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm
LEO Pharma
Phase 1/2 Completed
NCT01892137 2025-02-24
Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%
LEO Pharma
Phase 1 Completed
NCT02124239 2025-02-24
Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions
LEO Pharma
Phase 1 Completed
NCT02406014 2025-02-24
Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp
LEO Pharma
Phase 4 Completed
NCT02424305 2025-02-24
Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions
LEO Pharma
Phase 1 Completed
NCT02600598 2025-02-24
Biological Effects of LEO 43204 in Actinic Keratosis
LEO Pharma
Phase 1 Completed
NCT02650505 2025-02-24
A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel
LEO Pharma
Phase 1 Completed
NCT05741294 2025-02-20
A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses
Almirall, S.A.
Phase 4 Completed
NCT05387525 2025-02-11
AKtive
Almirall, S.A.
Phase 4 Active not recruiting
NCT04969419 2025-01-14
Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo
Momentum Data
Completed
NCT05365386 2024-12-03
Efficacy and Safety of Tixel Treatment on Facial and/or Scalp Actinic Keratoses.
Novoxel Ltd.
Phase NA Completed
NCT05060237 2024-10-17
Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
Biofrontera Bioscience GmbH
Phase 1 Completed
NCT05260073 2024-09-20
PROAK
Almirall, S.A.
Completed
NCT05636800 2024-08-06
Microwave Treatment for Actinic Keratosis
Blackwell Device Consulting
Phase NA Active not recruiting
NCT06274320 2024-06-18
Effect of Lipikar Urea 30% Before Actinic Keratoses Treatment
Cosmetique Active International
Phase NA Recruiting
NCT05231044 2024-04-19
A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or Scalp
PharmaEssentia
Phase 3 Completed
NCT04552327 2024-03-05
KOHDIAK
Infectopharm Arzneimittel GmbH
Phase 3 Completed
NCT05725213 2024-02-23
ADL-PDT Under Routine Clinical Conditions in Patients With Actinic Keratosis
Galderma Laboratorium GmbH
Completed